Insight into pharmaceutical deals and trends
Get insights into the latest deals and deal trends from Pharma Intelligence. Understand the implications of recent deals as they relate to drug development, reimbursement, and beyond.
34 Total results for product and free and sample content found
The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.
Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.
Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.
Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.
Pink Sheet, Scrip, In Vivo
Keep up with advances in the critically important, emerging area of gene therapy. This transformative new category of medicines has the potential to treat more diseases – including complex and rare diseases – with longer-lasting effects than traditional medicines.
Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.
Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.
Topic Deal trends
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: